[{"orgOrder":0,"company":"The Ritedose Corporation","sponsor":"Verona Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Ensifentrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"The Ritedose Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"The Ritedose Corporation \/ Verona Pharma","highestDevelopmentStatusID":"14","companyTruncated":"The Ritedose Corporation \/ Verona Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by The Ritedose Corporation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BOS Manchester
                          Not Confirmed
                          BOS Manchester
                          Not Confirmed

                          Details : Verona partnered with Ritedose for the development and manufacturing partner of Ohtuvayre (ensifentrine), a new novel product for Chronic Obstructive Pulmonary Disease.

                          Brand Name : Ohtuvayre

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 17, 2024

                          Lead Product(s) : Ensifentrine

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Sponsor : Verona Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank